ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Janssen, the pharmaceutical arm of Johnson & Johnson, will pay MacroGenics $75 million to license the bispecific antibody MGD015. In preclinical studies, MGD015 blocks both CD3 and an undisclosed tumor target with the goal of redirecting T cells to kill cells that overexpress the undisclosed antigen. This is the second pact between Janssen and MacroGenics. The companies are already developing MGD011, a bispecific molecule targeting CD19 and CD3, as a blood cancer treatment.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X